All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
DREAMM-8: Belantamab mafodotin in lenalidomide-exposed patients with RRMM
Bookmark this article
|
Analysis of the phase III DREAMM-8 trial (NCT04484623) of belantamab mafodotin, pomalidomide, and dexamethasone (BPd) compared with pomalidomide, bortezomib, and dexamethasone (PVd), in lenalidomide-exposed patients with relapsed/refractory multiple myeloma (RRMM) by Dimopoulos et al.1 has been published in The New England Journal of Medicine this week. The primary end point was progression-free survival (PFS), and disease response and safety were also assessed.
|
| Key learnings: |
|
The DREAMM-8 trial met its primary endpoint; BPd significantly improved PFS (12-month PFS of 71% vs 51% for PVd) and offers deeper, more durable responses compared with PVd in patients with RRMM who have been exposed to lenalidomide. |
|
The high incidence of ocular events with BPd (89%) requires careful management and dose adjustments but does not negate the substantial benefits in disease control. |
|
These findings suggest BPd could be a valuable therapeutic option for managing RRMM, particularly in lenalidomide-refractory cases. |
- Dimopoulos M, Beksac M, Pour L, et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024. Online ahead of print. DOI: 10.1056/NEJMoa2403407.
Your opinion matters
59 votes - 53 days left ...
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox